Macquarie Group
AVEO

Macquarie Group’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Macquarie Group’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-745
Closed -$5K – 1959
2019
Q2 		$5K Buy
+745
New +$6.38K ﹤0.01% 1816

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Macquarie Group's AVEO Position: Q3 2019 in Review

Macquarie Group sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2019, closing a stake of 745 shares — an estimated $5K sold.

Macquarie Group first reported a position in AVEO in Q2 2019 and held it in 1 quarter. The position peaked at $5K in Q2 2019. 59 funds tracked by Wall St. Rank hold AVEO as of Q3 2019.

  • Macquarie Group reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Macquarie Group sold 745 AVEO Pharmaceuticals, Inc. shares in Q3 2019, an estimated $5K.
  • Macquarie Group first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Macquarie Group's AVEO Pharmaceuticals, Inc. position peaked at $5K in Q2 2019.
  • 59 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2019.

Based on Macquarie Group's 13F filing for Q3 2019, filed 14 Nov 2019.